Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains...

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains 14.6% after reporting Q3 revenue of $93M and EPS of $0.40; while the latter missed by $0.33, the former beat by $2.2M, and investors appear reassured by positive comments regarding market acceptance of the company's Ampyra MS drug, made in partnership with ELN.